Summary & Overview
HCPCS J1110: Dihydroergotamine Mesylate Injection, 1 mg
HCPCS Level II code J1110 denotes an injectable dose of dihydroergotamine mesylate billed per 1 mg. This parenteral migraine therapy remains clinically significant for patients with acute, severe migraine attacks who require injectable agents when oral therapies are ineffective or contraindicated. Nationally, use of parenteral migraine treatments has implications for outpatient infusion capacity, emergency department management of headache, and payer coverage policy.
Key payers included in this analysis are Aetna, Blue Cross Blue Shield, Cigna, UnitedHealthcare, and Medicare. Readers will find concise benchmarks on coverage patterns, typical reimbursement considerations, and payer policy themes affecting access to parenteral migraine therapy. The publication also outlines clinical context for use, common sites of service where J1110 is administered, and typical billing considerations relevant to clinicians and revenue cycle teams.
The report covers benchmark measures and policy updates affecting billing and coverage for injectable dihydroergotamine, summarizes payer approaches to prior authorization and site-of-care requirements, and highlights billing nuances for per-milligram drug codes. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code J1110 represents an injection formulation of dihydroergotamine mesylate, billed per 1 mg. This medication is typically used for acute treatment of migraine and severe headache disorders when administered parenterally.
-
Service type: Injectable medication administration (parenteral drug)
-
Typical site of service: Ambulatory infusion centers, hospital outpatient departments, emergency departments, and physician office settings where parenteral migraine therapy is delivered.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with acute severe migraine or refractory cluster headache presenting to an ambulatory infusion clinic or emergency department after oral therapies failed or were contraindicated. The clinician evaluates migraine history, current medications (notably triptans and ergot derivatives), cardiovascular risk factors, and pregnancy status. Because J1110 represents dihydroergotamine mesylate injection per 1 mg, the medication is administered parenterally (intramuscular, subcutaneous, or intravenous) by an authorized clinician or nurse under protocol. Vital signs and cardiac history are reviewed due to vasoconstrictive effects; antiemetics (e.g., prochlorperazine, metoclopramide) may be given prior to or concurrently to improve tolerability. Typical workflow: clinician orders J1110 dose (often 1 mg increments up to a specified total), pharmacist verifies dosing and interactions (especially with potent CYP3A4 inhibitors and co-administration with triptans), nurse prepares and documents administration route, time, lot number, and any immediate adverse reactions. Patients are observed for a short period post-injection for efficacy and safety before discharge or admission for continued infusion therapy if needed. Typical sites of service include hospital outpatient infusion centers, emergency departments, physician offices with infusion capability, and ambulatory infusion suites.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|